Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 12, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
- Employee Share Option Plan: On December 10, 2003, the GlaxoSmithKline Employee Trust transferred 9,986 Ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- US Retirement Savings Plan: On December 11, 2003, the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 18,767,462 to 18,764,201. This movement occurred at an average price of $44.60.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses exclusively on regulatory disclosures regarding director interests.
Key Facts for Investor Verification
- Directors Dr. J-P Garnier and Mr. J D Coombe hold interests in the GSK Trust, which transferred 9,986 shares to plan participants.
- Director Dr. J P Garnier holds a potential interest in the US Retirement Savings Plan, which saw a reduction of 3,261 ADRs.
- The average price for the ADR movement in the US Retirement Savings Plan was $44.60.
- No financial performance metrics or strategic outlook are included in this specific filing.